GlassScriptPhysician profile
Jerry R Tanner
NPI 1962580480
$17,617.57
in general payments reported to CMS, 2019-2025
23 companies · $90.26 in 2025
The $90.26 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $617 · 2021: $118 · 2022: $229 · 2023: $343 · 2024: $1,483 · 2025: $90.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Travel and Lodging: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.83 |
| Travel and Lodging | $899.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14,011.65 | 2019-2023 | Rybelsus |
| Medtronic, INC. | $1,445.47 | 2022-2024 | Minimed 780g, Minimed 770g |
| Senseonics, Incorporated | $826.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $459.53 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $173.81 | 2019-2020 | |
| Lilly USA, LLC | $130.25 | 2019-2024 | Mounjaro |
| Amgen INC. | $129.60 | 2019-2025 | Repatha |
| Allergan, INC. | $65.91 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $48.82 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $48.47 | 2019 | |
| Glaxosmithkline, LLC. | $42.58 | 2019-2024 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.42 | 2019-2020 | |
| Abiomed | $24.55 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.49 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.23 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.53 | 2023 | Breztri |
| Xeris Pharmaceuticals, INC. | $18.60 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.84 | 2022 | |
| Medtronic Minimed, INC. | $16.70 | 2020 | |
| Rgh Enterprises LLC | $16.17 | 2025 | |
| Merck Sharp & Dohme LLC | $14.72 | 2019 | |
| Dexcom, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.